MBL949 / Novartis - LARVOL DELTA

A growth-differentiation factor 15 receptor agonist in randomized placebo-controlled trials in healthy or obese persons. (PubMed, J Clin Endocrinol Metab) - P2 | "The prolonged half-life of MBL949 supports biweekly dosing in patients. MBL949 had an acceptable safety profile. The robust weight loss observed in nonclinical species did not translate to weight loss efficacy in humans."

Clinical • Journal • Gastrointestinal Disorder • Genetic Disorders • Obesity • GDF15 • RET • TGFB1

Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM (clinicaltrials.gov) - P2 | N=126 | Terminated | Sponsor: Novartis Pharmaceuticals | Completed ➔ Terminated; The tolerability to benefit ratio based on maximum weight loss observed was not considered favorable at the doses studied and the study was terminated early

Trial termination • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM (clinicaltrials.gov) - P2 | N=127 | Completed | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM (clinicaltrials.gov) - P2 | N=127 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM (clinicaltrials.gov) - P2 | N=106 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Study to Assess Safety, Tolerability and Efficacy of SC Administered MBL949 in Obese Participants With or Without T2DM (clinicaltrials.gov) - P2; N=106; Not yet recruiting; Sponsor: Novartis Pharmaceuticals

Clinical • New P2 trial • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus